KBY Biotech Indexv0.0.34
Search
← Pipeline|RIN-582

RIN-582

Phase 3
By Ring Ther
Source: Trial-derived·Trials: 4
Modality
ADC
MOA
BCMA ADC
Target
SMN2
Pathway
Autophagy
IgAN
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Aug 2029
Phase 3Current
NCT03565942
2,857 pts·IgAN
2025-04→2025-07·Completed
NCT06440126
2,757 pts·IgAN
2025-10→TBD·Terminated
NCT05462489
1,086 pts·IgAN
2023-02→2029-08·Completed
+1 more trial
7,159 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-07-198mo agoPh3 Readout· IgAN
2027-10-021.5y awayPh3 Readout· IgAN
2029-08-253.4y awayPh3 Readout· IgAN
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Complet…
P3
Complet…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2025-07-19 · 8mo ago
IgAN
Ph3 Readout
2027-10-02 · 1.5y away
IgAN
Ph3 Readout
2029-08-25 · 3.4y away
IgAN
CompletedTerminated|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT03565942Phase 3IgANCompleted2857EFS
NCT06440126Phase 3IgANTerminated2757LiverFat
NCT05462489Phase 3IgANCompleted1086HAM-D
NCT08587352Phase 3IgANCompleted459BodyWt
Competitors (10)
DrugCompanyPhaseTargetMOA
AZN-3724AstraZenecaPreclinicalPSMABCMA ADC
NVO-6275Novo NordiskPhase 1SMN2BTKi
OlpatinibGSKPreclinicalPD-L1BCMA ADC
TAK-5300TakedaPhase 1SMN2AuroraAi
GIL-9779Gilead SciencesPhase 1IL-17ABCMA ADC
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
REG-647RegeneronPreclinicalSMN2SOS1i
SematenlimabSamsung BiologicsPhase 3PI3KαBCMA ADC
OlpafutibatinibImmunocoreApprovedSMN2Menini
TixatapinarofRecursionApprovedFGFRBCMA ADC